V-type PML::RARA fusion transcripts in APL have shown decreased in vitro responsiveness to ARTA [53] and are reported to display decreased sensitivity to standard ARTA treatments [53,54] and a higher failure rate of standard treatments [55]. This evidence concerns the gene PML and acute promyelocytic leukemia.